Sol-Gel Technologies ROE 2016-2024 | SLGL

Current and historical return on equity (ROE) values for Sol-Gel Technologies (SLGL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Sol-Gel Technologies ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2024-06-30 $-0.02B $0.04B -40.00%
2024-03-31 $-0.02B $0.03B -56.44%
2023-12-31 $-0.03B $0.04B -64.37%
2023-09-30 $-0.03B $0.04B -65.54%
2023-06-30 $-0.03B $0.05B -57.46%
2023-03-31 $-0.02B $0.04B -43.72%
2022-12-31 $-0.02B $0.04B -31.75%
2022-09-30 $0.01B $0.05B 9.85%
2022-06-30 $0.01B $0.05B 18.27%
2022-03-31 $0.00B $0.05B 2.15%
2021-12-31 $0.00B $0.06B 6.56%
2021-09-30 $-0.02B $0.04B -38.20%
2021-06-30 $-0.03B $0.04B -55.67%
2021-03-31 $-0.03B $0.05B -47.06%
2020-12-31 $-0.03B $0.05B -48.13%
2020-09-30 $-0.03B $0.06B -49.59%
2020-06-30 $-0.03B $0.07B -45.90%
2020-03-31 $-0.03B $0.07B -44.64%
2019-12-31 $-0.03B $0.05B -44.44%
2019-09-30 $-0.03B $0.06B -50.63%
2019-06-30 $-0.03B $0.06B -49.01%
2019-03-31 $-0.03B $0.06B -47.14%
2018-12-31 $-0.03B $0.06B -42.86%
2018-03-31 $-0.01B $0.09B -126.32%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.012B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00